Search research articles
Contact Us
Filters
Showing results (1-10 of 509) with videos related to
Page
of 51
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
November 7, 2024
Targeted therapy in prostate cancer: beyond PSMA
Michael J Morris
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2015
Failure of ELM-PC 5: an ineffective drug or an unfit end point?
Michael J Morris
Nature Clinical Practice. Oncology
|
October 5, 2006
Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
The timing of molecular imaging in prostate cancer
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2025
The use of PSMA PET/CT imaging as an endpoint in clinical trials of prostate cancer
Michael J Morris
American Journal of Respiratory and Critical Care Medicine
|
November 1, 2014
Reply: Respiratory symptoms in service members returning from Afghanistan and Iraq
Michael J Morris
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Reply to K. Lu
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
December 1, 2023
The National Cancer Institute's Clinical Trials Innovation Unit
Michael J Morris, Sheila Prindiville
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 1, 2022
From Concept to Regulatory Drug Approval: Lessons for Theranostics
Marlon Perera, Michael J Morris
Annals of the American Thoracic Society
|
February 2, 2017
Reply: Excessive Dynamic Airway Collapse: Fact, Fiction, or Flow Limitation
Michael J Morris, Septimiu Murgu
Page
of 51
Search research articles
Search
Showing results (1-10 of 509) with videos related to
Sort By:
Page
of 51
Clinical Advances in Hematology & Oncology : H&O
|
November 7, 2024
Targeted therapy in prostate cancer: beyond PSMA
Michael J Morris
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2015
Failure of ELM-PC 5: an ineffective drug or an unfit end point?
Michael J Morris
Nature Clinical Practice. Oncology
|
October 5, 2006
Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
The timing of molecular imaging in prostate cancer
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2025
The use of PSMA PET/CT imaging as an endpoint in clinical trials of prostate cancer
Michael J Morris
American Journal of Respiratory and Critical Care Medicine
|
November 1, 2014
Reply: Respiratory symptoms in service members returning from Afghanistan and Iraq
Michael J Morris
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Reply to K. Lu
Michael J Morris
Clinical Advances in Hematology & Oncology : H&O
|
December 1, 2023
The National Cancer Institute's Clinical Trials Innovation Unit
Michael J Morris, Sheila Prindiville
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 1, 2022
From Concept to Regulatory Drug Approval: Lessons for Theranostics
Marlon Perera, Michael J Morris
Annals of the American Thoracic Society
|
February 2, 2017
Reply: Excessive Dynamic Airway Collapse: Fact, Fiction, or Flow Limitation
Michael J Morris, Septimiu Murgu
Page
of 51